Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Mutations in DNA methyltransferase 3A (DNMT3A) have been detected in autism and related disorders, but how these mutations disrupt nervous system function is unknown. Here, we define the effects of DNMT3A mutations associated with neurodevelopmental disease. We show that diverse mutations affect different aspects of protein activity but lead to shared deficiencies in neuronal DNA methylation. Heterozygous DNMT3A knockout mice mimicking DNMT3A disruption in disease display growth and behavioral alterations consistent with human phenotypes. Strikingly, in these mice, we detect global disruption of neuron-enriched non-CG DNA methylation, a binding site for the Rett syndrome protein MeCP2. Loss of this methylation leads to enhancer and gene dysregulation that overlaps with models of Rett syndrome and autism. These findings define the effects of DNMT3A haploinsufficiency in the brain and uncover disruption of the non-CG methylation pathway as a convergence point across neurodevelopmental disorders.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716597PMC
http://dx.doi.org/10.1016/j.celrep.2020.108416DOI Listing

Publication Analysis

Top Keywords

dnmt3a haploinsufficiency
8
neurodevelopmental disorders
8
disorders mutations
8
define effects
8
effects dnmt3a
8
dna methylation
8
rett syndrome
8
dnmt3a
6
haploinsufficiency behavioral
4
behavioral deficits
4

Similar Publications

Preventing CpG hypermethylation in oocytes safeguards mouse development.

Dev Cell

August 2025

Friedrich Miescher Institute for Biomedical Research, 4056 Basel, Switzerland; Faculty of Sciences, University of Basel, 4056 Basel, Switzerland. Electronic address:

Except for regulatory CpG-island sequences, genomes of most mammalian cells are widely DNA-methylated. In oocytes, though, DNA methylation (DNAme) is largely confined to transcribed regions. The mechanisms restricting de novo DNAme in oocytes and their relevance thereof for zygotic genome activation and embryonic development are largely unknown.

View Article and Find Full Text PDF

In 1974, Vanden Berghe et al described a distinct hematologic disorder associated with acquired, interstitial deletion of part of the long arm of chromosome 5. This condition is now classified as myelodysplastic syndrome (MDS) with isolated deletion 5q, or MDS-del(5q). The common deletion region 5q32-5q33 contains several genes and microRNAs whose expression levels are reduced in hematopoietic cells, consistent with the loss of one allele.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists found a new type of genetic change called t(X;21) in some patients with blood diseases like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
  • This change happened along with other mutations in certain genes, but it didn't create new fusion genes as might be expected.
  • They discovered that this genetic change is linked to the loss of two important genes (BCOR and RUNX1), which affects how cells behave in these diseases.
View Article and Find Full Text PDF

Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer.

View Article and Find Full Text PDF

Expanding the phenotype of DNMT3A as a cause a congenital myopathy with rhabdomyolysis.

Neuromuscul Disord

June 2023

Adelaide Medical School, The University of Adelaide, South Australia, Australia; Department of Genetics & Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia.

Pathogenic variants in DNMT3A are most commonly associated with Tatton-Brown-Rahman Syndrome (TBRS), but includes other phenotypes such as Heyn-Sproul-Jackson syndrome and acute myeloid leukemia (AML). We describe a patient presenting to the neuromuscular clinic with a de novo missense variant in DNMT3A where the striking clinical feature is that of a congenital myopathy with associated episodes of rhabdomyolysis, severe myalgias and chest pain along with phenotypic features associated with TBRS. Muscle biopsy showed minor myopathic features and cardiac investigations revealed mildly impaired bi-ventricular systolic function.

View Article and Find Full Text PDF